Literature DB >> 17600362

Prospective screening in liver transplant recipients by panfungal PCR-ELISA for early diagnosis of invasive fungal infections.

Parisa Badiee1, Parivash Kordbacheh, Abdolvahab Alborzi, Seyedali Malekhoseini, Farideh Zeini, Hosein Mirhendi, Mahmood Mahmoodi.   

Abstract

Invasive fungal infections after liver transplantation (LT) have resulted in high mortality and potentially fatal complications. This study was undertaken to determine the accuracy of the panfungal polymerase chain reaction enzyme link immunosorbent assay (PCR-ELISA) method in early diagnosis of invasive fungal infections in liver transplant recipients (LTRs). A total of 48 liver recipients (cadaver donors) were followed for fungal infections for a period of at least 6 months. All clinical samples were cultured and a direct microscopic examination was performed. Blood samples were cultured by bedside inoculation onto BACTEC medium. Whole blood specimens were collected prospectively once per week and were evaluated for any invasive fungal infections by panfungal PCR and PCR-ELISA. Among 48 transplant recipients between September 2004 and January 2006 (22 females, 28 males, mean age = 34.4 yr), 40 recipients (83.3%) had Candida colonization in different sites of their body before LT. In proven and probable recipients for panfungal PCR-ELISA, the sensitivity, specificity, and positive and negative predictive values were 83.3%, 91.7%, 76.9%, and 94.3%, respectively. By PCR assay, fungal infections were diagnosed in 10 recipients (20.8%). The mean interval time from transplantation to development of fungal infection was 61.4 days (range, 20-150 days) and time of infection in blood before any clinical signs was 7-70 days with mean of 21.4 days. The etiologic agents were Candida albicans (9 cases) and Aspergillus fumigatus (1 case). Use of PCR-ELISA in LTRs may not only improve the ability of early diagnosis of invasive fungal infections (IFIs) when positive results are obtained, but also would provide more confidence to exclude a diagnosis of IFIs when negative results are obtained.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600362     DOI: 10.1002/lt.21175

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  6 in total

Review 1.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia.

Authors:  Manuel Cuenca-Estrella; Yolanda Meije; Carmen Diaz-Pedroche; Alicia Gomez-Lopez; Maria J Buitrago; Leticia Bernal-Martinez; Carlos Grande; Rafael San Juan; Manuel Lizasoain; Juan L Rodriguez-Tudela; Jose M Aguado
Journal:  J Clin Microbiol       Date:  2008-12-24       Impact factor: 5.948

3.  The Genotype Frequency of CYP2C19 Enzyme after Liver Transplantation.

Authors:  P Badiee; Z Hashemizadeh; S A Malek-Hosseini; B Geramizadeh
Journal:  Int J Organ Transplant Med       Date:  2019-05-01

Review 4.  Opportunistic invasive fungal infections: diagnosis & clinical management.

Authors:  Parisa Badiee; Zahra Hashemizadeh
Journal:  Indian J Med Res       Date:  2014-02       Impact factor: 2.375

5.  Comparison of anti-Candida activities of the ancient plants Lawsonia inermis and Ziziphus spina christi with antifungal drugs in Candida species isolated from oral cavity.

Authors:  Maryam Mardani; Parisa Badiee; Mahnaz Gharibnavaz; AmirReza Jassebi; Hadis Jafarian; Fatemeh Ghassemi
Journal:  J Conserv Dent       Date:  2018 Jul-Aug

6.  Antifungal Effects of Common Mouthwashes on Candida Strains Colonized in the Oral Cavities of Liver Transplant Recipients in South Iran in 2014.

Authors:  Ali Dehghani Nazhvani; Pardis Haddadi; Parisa Badiee; Seyed Ali Malekhoseini; Hadis Jafarian
Journal:  Hepat Mon       Date:  2016-01-30       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.